Boston-based Life Biosciences has successfully closed an $80 million Series D financing, fully subscribed, which will bolster operations through the latter half of 2027. This funding is earmarked for advancing its Phase 1 clinical trial of ER-100, targeting conditions such as open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. The trial aims to evaluate the safety, tolerability, and various aspects of visual function and is registered under NCT07290244.

The significance of this development lies in Life Biosciences’ innovative approach to Partial Epigenetic Reprogramming (PER), utilizing three transcription factors—OCT4, SOX2, and KLF4 (collectively referred to as OSK)—to partially rejuvenate the epigenome of aged and injured cells. This technique positions the company to potentially address a spectrum of age-related diseases, which could have profound implications for therapeutic strategies in longevity science. The successful execution of the ER-100 trial could pave the way for new treatment paradigms in ocular health and beyond.

The key takeaway from this financing round is its potential to expand the therapeutic pipeline beyond ER-100, indicating a strategic shift in how Life Biosciences plans to leverage its PER platform. This could accelerate the development timelines for emerging therapies targeting not only ocular conditions but also other age-related ailments, thereby reshaping research priorities and funding allocations in the field of aging biology. As the company progresses, it may set new standards for how epigenetic interventions are integrated into clinical practice, ultimately enhancing healthspan and longevity outcomes.

Source: longevity.technology